ImmunogenX

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
ImmunogenX is a clinical-stage therapeutic and diagnostic company focused on celiac disease (CD). Both Rx and Dx treatments represent unmet needs for a critical disease and as developers of leading technologies we are positioned to be a Category King in the CD market space. Our lead development is the therapeutic drug Latiglutenase, which has undergone several successful clinical trials and is in final Phase 2b trials before commencing the Phase 3 registration trial.

We are a uniquely qualified company that understands the market, has the business and technical acumen, is passionate about the societal benefits we can offer to the celiac community, and have the relationships and connections to partner with financial and strategic partners to execute on the entire regulatory and commercial roadmap.

For investors we provide the potential for enormous value creation and early exit opportunity.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Latiglutenase
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
ImmunogenX